Patent · US Active

Cell-based anti-cancer compositions with reduced toxicity and methods of making and using the same

US10202463B2 · kind B2 · utility

0Cited by
0References
10Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJun 30, 2016
Grant dateFeb 12, 2019
Priority date
Expiry dateJun 30, 2036

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2320/32
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Isolated pluralities of T cells which recognize at least one epitope of an intestinal cancer antigen or CNS cancer antigen and pharmaceutical compositions comprising the same are disclosed. Methods of making a plurality of T cells that recognize at least one epitope of an intestinal cancer antigen or CNS cancer antigen are also disclosed. Methods of treating an individual who has been diagnosed with cancer of a mucosal tissue or preventing such cancer in an individual at elevated risk are disclosed as are nucleic acid molecules that comprise a nucleotide sequence that encode proteins that recognize at least one epitope of an intestinal cancer antigen or CNS cancer antigen and T cells comprising such nucleic acid molecules.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.